BioSpecifics Technologies Corp

BioSpecifics Technologies — Investor Presentation (November 2014)

28 slides from BioSpecifics Technologies's investor presentation, Nov 13, 2014

  1. Slide 1: Innovators in the development & commercialization of injectable collagenase

    Innovators in the development & commercialization of INJECTABLE COLLAGENASE a 5 BioSpecifics November 2014

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation includes “forward-looking statements” within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are “forward-looking statements”

  3. Slide 3: Corporate Overview

    Corporate Overview BioSpecifics is a profitable, commercial-stage biopharma company maximizing the potential of collagenase clostridium histolyticum or CCH (XIAFLEX®) for multiple commercial and clinical indications XIAFLEX is marketed in the U.S. by strategic partner, Auxilium Pharmaceuticals for D

  4. Slide 4: Vast Therapeutic Potential of CCH

    Vast Therapeutic Potential of CCH CCH provides a first-in-class, minimally invasive nonsurgical treatment option for conditions and diseases caused by collagen accumulation where current treatment options are limited BioSpecifics has positive results in 12 indications: Dupuytren’s contracture* Froze

  5. Slide 5: Marketed Indications for XIAFLEX

    Marketed Indications for XIAFLEX Marketed * Dupuytren’s Decision on approval in Japan expected in mid-2015 Contracture Peyronie’s Decision on approval in EU expected in 1Q15 Disease

  6. Slide 6: Commercial Success for XIAFLEX

    Commercial Success for XIAFLEX Impressive Growth In Both Indications Total XIAFLEX revenues up 118% in 3Q14 over 3Q13 XIAFLEX U.S. net revenues for both indications were $34.6M over $15.9M in 3Q13, a 118% increase U.S. XIAFLEX revenues up 31% in 3Q14 over 2Q14 Est. 5,863 vials sold in 3Q14 for Dupuy

  7. Slide 7: XIAFLEX for Dupuytren's Contracture

    XIAFLEX for Dupuytren’s Contracture Formation of a collagen cord in the hand causing one or Definition and more fingers to contract toward the palm Key Complications Limits range of motion of the fingers often resulting in physical disability and impaired quality of life First and Only FDA- and EMA-

  8. Slide 8: XIAFLEX Label Expansion

    XIAFLEX Label Expansion sBLA Approved in October 2014 Expanded label allows for treatment of up to two Dupuytren’s contracture joints in the same hand during a single office visit SDI Health LLC estimates 35 to 40% of annual Dupuytren’s contracture surgeries in U.S. are performed to treat two or mor

  9. Slide 9: Dupuytren's Contracture Commercial Opportunity

    Dupuytren’s Contracture Commercial Opportunity Focus on Consistent U.S. Sales Growth Expansion in New Markets and Patient Subpopulations 300K patients diagnosed annually 32% market share YTD among all procedures Good sales momentum by Sobi within European markets Asahi Kasei submitted regulatory app

  10. Slide 10: XIAFLEX for Peyronie's Disease

    XIAFLEX for Peyronie’s Disease Definition & Key Complications First and Only FDA- Approved PD Treatment Pre-treatment: Excess of inelastic collagen causing penile curvature; penis can bend at 90° angle during erection in severe cases Pain with erection, penile shortening, indentations, erectile dysf

  11. Slide 11: Peyronie's Disease Commercial Opportunity

    Peyronie’s Disease Commercial Opportunity 95K patients* diagnosed in 2013 but believed to be U.S. Market underdiagnosed Opportunity Up to eight injections (four treatment cycles of two injections) in-office Auxilium Advantage™ - assists patients and providers in accessing XIAFLEX Providers: facilita

  12. Slide 12: Commercial Progress

    Commercial Progress Focused, disciplined initial product rollout 5,000-6,500 patients receive invasive treatment for Peyronie’s disease each year (plication, grafting, prosthesis surgery or verapamil injections) ~400 urologists account for 90% of PD surgeries REMS certification of urologists 1,450 T

  13. Slide 13: Commercial Progress (Cont.)

    Commercial Progress (Cont.) Reimbursement approval by payers (Auxilium Advantage) All eight Medicare beneficiaries confirmed coverage at policy level; 29 major commercial health plans have approved patients for treatment Listed as 'medically necessary’ in Clinical Policy Bulletin, when administered

  14. Slide 14: XIAFLEX Pipeline Programs

    XIAFLEX Pipeline Programs ats] recinal| Pnes | rasa [raves | Marte pozen e Top-line data in 1Q15 Canine Auxilium to determine development plan Lipoma * Human Complete enrollment in Phase 2 in 1Q15 Lipoma Cellulite Initiation of Phase 2b in 2Q15 *Uterine CITT Fibroids suitles *BioSpecifics-managed de

  15. Slide 15: CCH for Lipomas

    CCH for Lipomas Clinical Phase 2 Opt-In Study Managed by BioSpecifics Encapsulated deposits of benign fatty tumors; detected as bulges Benson under the skin Potential to be No FDA-approved pharmaceutical therapies available Only Approved Nonsurgical Therapy Surgery not practical for patients with mu

  16. Slide 16: Positive Phase Clinical Trial Results in Humans Reported in January 2014

    Positive Phase 2 Clinical Trial Results in Humans Reported in January 2014 Open label, dose escalation Phase 2 trial for humans with benign subcutaneous lipomas showed: Statistically significant (p<0.0001) reduction in primary endpoint of visible surface area of lipoma as measured by caliper, combin

  17. Slide 17: CCH for Lipomas in Canines

    CCH for Lipomas in Canines Auxilium to Manage Development Program Key Complications Potential to be Only Approved Nonsurgical Therapy U.S. Market Opportunity $500K Opt-In Payment to BioSpecifics Encapsulated deposits of benign fatty tumors can cause seriously restrict motion in older dogs Most frequ

  18. Slide 18: Opt-In Decision Based on Phase 2 Canine Trial

    Opt-In Decision Based on Chien-804: Encouraging Placebo-Controlled, Phase 2 CCH Trial Randomized trial conducted in canines with benign subcutaneous lipomas. Study did not meet primary endpoint but demonstrated benefit in secondary measures: Responder analysis: Visible surface area as measured by ca

  19. Slide 19: CCH for Uterine Fibroids

    CCH for Uterine Fibroids New Study Results Reported in October 2014 Benign tumors E Te08 Definition & Pain, decreased fertility, H = Key Complications miscarriage, heavy menstrual 5 ae bleeding and frequent urination ae =e ; arene bso Potential to be pose omer a - er q00 025 050 400 200 - ysterectom

  20. Slide 20: CCH for Frozen Shoulder Syndrome

    CCH for Frozen Shoulder Syndrome Top-line Data from Phase 2b Study Expected in 1Q15 Definition and Key Complications Potential to be Only Approved Nonsurgical Therapy Market Opportunity Top-line Data from Phase 2b Study Expected in 1Q15 Source: Auxilium Pharmaceuticals, In. Inflammation and thickeni

  21. Slide 21: Statistically Significant CCH Dose Response in Phase 2a Study

    Statistically Significant CCH Dose Response in Phase 2a Study 2 3 t 1 Statistically significant improvements in oO valscum Mf | * sonar ‘both the 0.58 mg(1ml) and 0.58 350 to Exercise Cohor 1 Shoulder Abduction mg(2mL) cohorts over baseline scores a External Rotation vs. the exercise-only group: Hie

  22. Slide 22: CCH for Cellulite

    CCH for Cellulite Positive Phase 2a Top-line Results Reported in 3Q14 Skin dimpling as a result of collagen fibrous septae held in an Definition irregular pattern under the skin, occurring mainly on the buttocks, lower limbs, and abdomen de eee « Affects 85-98% of women (est.) and rarely in men ppor

  23. Slide 23: CCH for Cellulite

    CCH for Cellulite Initiation of Phase 2b Study Expected in 2Q15 Top-line Data from Phase 2a Study Mid and high level CCH doses demonstrated statistically significant improvement in cellulite across all endpoints 68% of mid and high dose groups reported being “Satisfied” or “Very Satisfied” with trea

  24. Slide 24: Auxilium Partnership for Development and Commercialization of CCH

    Auxilium Partnership for Development and Commercialization of CCH >$48M Received from Auxilium Future Payments Due to BioSpecifics from Auxilium Auxilium Opt-In Rights Milestone Payments. from AUXL Partnerships $48M received in licensing, sublicensing, milestone, COGS, and royalty payments as of Sep

  25. Slide 25: Corporate Highlights

    Corporate Highlights Vast opportunity for growth in revenues from XIAFLEX sales and approval of CCH in new indications Strong Intellectual Property Portfolio Long-term patent protection for injectable collagenase: Dupuytren’s Contracture: XIAFLEX has Orphan Drug protection in U.S. until 2017; Drug p

  26. Slide 26: Consistently Profitable Annually

    Consistently Profitable Annually 3Q14 Financial Highlights For the quarter For the year ended ended 09/30/14 12/31/13 (unaudited) (unaudited) Cash and equivalents, short term investments $s 17,500,003 $ 12,591,825 Income Statement Revenues $ 4,012,787 $ 14,467,240 Other income 8,121 26,202 Costs and

  27. Slide 27: Anticipated Upcoming Milestones

    Anticipated Upcoming Milestones Upcoming Milestones *Human Lipomas O Complete enrollment in Phase 2 placebo-controlled opt-in trial in 1Q15 eae Q Auxilium to determine development path Seen O Ongoing pre-clinical studies; refine development plan puperen Q Decision on approval by PMDA in Japan expect

  28. Slide 28: Innovators in the development & commercialization of injectable collagenase

    Innovators in the development & commercialization of INJECTABLE COLLAGENASE ridium histolticUM, ss = November 2014

Biospecifics Technologies — Investor Presentation (November 2014) on 6ix